185525-42-2Relevant articles and documents
NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
-
Paragraph 0256; 0258, (2019/05/16)
Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):
NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
-
, (2018/10/19)
This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.
SPIRO-PIPERIDINE DERIVATIVES
-
Page/Page column 28; 29, (2008/12/06)
Present invention is concerned with novel indol- 2-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention andlor treatment of anxiety and depressive disorders and other diseases. The compounds of present invention have the general Formula (I) wherein R1 to R 11 and X are as defined in the description